USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TUNITAS THERAPEUTICS, INC.
Address:
409 Illinois Street
San Francisco, CA
EIN:
126147688
DUNS:
829828149
Number of Employees:
8
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $743,494.00 2
SBIR Phase II $6,000,000.00 2
STTR Phase I $172,386.00 1
STTR Phase II $1,699,968.00 1

Award List:

Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Nolan Sigal
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is to develop and commercialize a new approach for allergen specific immunotherapy as treatment for cat allergy. This proposal will provide a novel therapeutic for a very importan t inhalant allergen and serve as a model… More

Allergen???Fc-gamma1 proteins to treat food allergy

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$172,386.00
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Research Institution:
University Of California Los Angeles
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% ofyoung children. It is clearly on the rise.… More

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$443,494.00
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and commercialize a novel biologic therapy for the treatment of allergic disease and particularly allergic asthma. Specifically, this proposal will provide the critical immunogenicity, mechanistic and biomarker data… More

A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of USpopulation, age 6-59, being skin test… More

Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy

Award Year / Program / Phase:
2012 / STTR / Phase II
Award Amount:
$1,699,968.00
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Research Institution:
UNIVERSITY OF CALIFORNIA LOS ANGELES
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective… More

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Nolan Sigal – 650-887-4747
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein… More